JP2024540196A - Ｃｃｒ２を標的とする抗体 - Google Patents

Ｃｃｒ２を標的とする抗体 Download PDF

Info

Publication number
JP2024540196A
JP2024540196A JP2024525765A JP2024525765A JP2024540196A JP 2024540196 A JP2024540196 A JP 2024540196A JP 2024525765 A JP2024525765 A JP 2024525765A JP 2024525765 A JP2024525765 A JP 2024525765A JP 2024540196 A JP2024540196 A JP 2024540196A
Authority
JP
Japan
Prior art keywords
antibody
seq
ccr2
human
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540196A5 (https=
JPWO2023072916A5 (https=
Inventor
マティアス マック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Granite Bio Ag
Original Assignee
Granite Bio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Granite Bio Ag filed Critical Granite Bio Ag
Publication of JP2024540196A publication Critical patent/JP2024540196A/ja
Publication of JP2024540196A5 publication Critical patent/JP2024540196A5/ja
Publication of JPWO2023072916A5 publication Critical patent/JPWO2023072916A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024525765A 2021-10-27 2022-10-25 Ｃｃｒ２を標的とする抗体 Pending JP2024540196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204904 2021-10-27
EP21204904.3 2021-10-27
PCT/EP2022/079744 WO2023072916A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Publications (3)

Publication Number Publication Date
JP2024540196A true JP2024540196A (ja) 2024-10-31
JP2024540196A5 JP2024540196A5 (https=) 2025-11-05
JPWO2023072916A5 JPWO2023072916A5 (https=) 2025-11-05

Family

ID=78413745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525765A Pending JP2024540196A (ja) 2021-10-27 2022-10-25 Ｃｃｒ２を標的とする抗体

Country Status (10)

Country Link
US (2) US12168692B1 (https=)
EP (1) EP4423131A1 (https=)
JP (1) JP2024540196A (https=)
KR (1) KR20240099211A9 (https=)
CN (1) CN118159562A (https=)
AU (1) AU2022378899A1 (https=)
CA (1) CA3231124A1 (https=)
IL (1) IL311476A (https=)
MX (1) MX2024004447A (https=)
WO (1) WO2023072916A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245988A1 (en) * 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2016079276A1 (en) 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease

Also Published As

Publication number Publication date
US20240392018A1 (en) 2024-11-28
AU2022378899A1 (en) 2024-03-07
MX2024004447A (es) 2024-05-08
KR20240099211A (ko) 2024-06-28
US12168692B1 (en) 2024-12-17
CN118159562A (zh) 2024-06-07
WO2023072916A1 (en) 2023-05-04
KR20240099211A9 (ko) 2025-12-10
EP4423131A1 (en) 2024-09-04
CA3231124A1 (en) 2023-05-04
IL311476A (en) 2024-05-01
US20250059288A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
JP7625656B2 (ja) 完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
TW202448940A (zh) 結合介白素4受體α之抗體及其使用方法
WO2022166977A1 (zh) 抗人il-36r抗体及其应用
US20250382362A1 (en) Antibodies targeting il3
US20250059288A1 (en) Antibodies targeting ccr2
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
US12304958B2 (en) Antibodies targeting ActRIIA and ActRIIB
HK40111251A (zh) 靶向ccr2的抗体
WO2024245988A1 (en) Antibodies targeting ccr2
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
WO2022262828A1 (zh) 抗il-36r抗体及其用途
HK40034272B (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251024